Home › Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
 

Keywords :   


Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

2014-10-22 15:11:12| Biotech - Topix.net

Ipsen and Lexicon Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan.

Tags: enter agreement licensing lexicon

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Forecast Discussion Number 18
03.07Hurricane Beryl Wind Speed Probabilities Number 18
03.07Hurricane Beryl Public Advisory Number 18
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Hurricane Beryl Forecast Advisory Number 18
03.07Hurricane Beryl Graphics
03.07Atlantic Tropical Weather Outlook
More »